Stock Traders Buy High Volume of Call Options on COMPASS Pathways (NASDAQ:CMPS)

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) saw some unusual options trading on Monday. Stock traders acquired 5,261 call options on the stock. This is an increase of approximately 420% compared to the typical daily volume of 1,012 call options.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group reduced their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, February 28th. Evercore ISI reiterated an "in-line" rating and issued a $6.00 target price (down previously from $11.00) on shares of COMPASS Pathways in a research report on Monday. Cantor Fitzgerald reissued an "overweight" rating and set a $12.00 target price on shares of COMPASS Pathways in a research note on Tuesday, May 27th. Stifel Nicolaus started coverage on shares of COMPASS Pathways in a research note on Thursday, February 27th. They issued a "buy" rating and a $11.00 price target on the stock. Finally, HC Wainwright reiterated a "buy" rating on shares of COMPASS Pathways in a report on Monday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, COMPASS Pathways has an average rating of "Moderate Buy" and a consensus price target of $17.00.

COMPASS Pathways Stock Down 3.6%

Shares of COMPASS Pathways stock traded down $0.10 during midday trading on Thursday, reaching $2.66. 4,335,050 shares of the company's stock traded hands, compared to its average volume of 1,163,635. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.18 and a current ratio of 10.18. COMPASS Pathways has a 52 week low of $2.25 and a 52 week high of $8.54. The company's 50 day simple moving average is $4.06 and its 200 day simple moving average is $3.86. The company has a market cap of $248.87 million, a price-to-earnings ratio of -1.34 and a beta of 2.25.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.03. Equities analysts expect that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On COMPASS Pathways

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMPS. Cerity Partners LLC bought a new position in shares of COMPASS Pathways in the first quarter valued at approximately $29,000. GAMMA Investing LLC lifted its position in COMPASS Pathways by 93.6% during the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock worth $30,000 after acquiring an additional 5,003 shares during the last quarter. Ethos Financial Group LLC bought a new stake in COMPASS Pathways during the first quarter valued at about $35,000. Flagship Harbor Advisors LLC boosted its holdings in COMPASS Pathways by 27.7% during the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after acquiring an additional 3,134 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in shares of COMPASS Pathways in the first quarter valued at about $41,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.